Please fill out the form below to register to
receive updates regarding Fidelis Animal Health and its products.
Ethiqa XR is the only FDA-indexed, cGMP-manufactured, extended-release buprenorphine indicated for the control of post-procedural pain in mice and rats. 1
1. Data on file. Fidelis Animal Health (f/k/a Fidelis Pharmaceuticals), North Brunswick, NJ; November 2021
IMPORTANT SAFETY INFORMATION For Rats and Mice: Only administer Ethiqa XR by subcutaneous injection. Ethiqa XR is not intended for intravenous, intra-arterial, intrathecal, intramuscular, or intra-peritoneal injection. Do not use on mice or rats with pre-existing respiratory deficiencies. Do not keep rats on wood chip-type bedding after administration of Ethiqa XR. Use caution with concomitant administration of Ethiqa XR with drugs that cause respiratory depression. For Humans: Ethiqa XR should only be administered by a veterinarian or laboratory staff trained in the handling of potent opioids. Protective clothing is recommended to avoid direct contact with human skin or mucus membranes which could result in absorption of buprenorphine and adverse reactions. Not for use in humans. For more information, consult the Prescribing Information including the Boxed Warning.
Not for use in humans. Keep out of reach of children. For more information, consult the Prescribing Information, including the Boxed Warning.